UK- Haleon, the parent company behind renowned brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its sole manufacturing site in the UK.

The move comes as part of a strategic review of Haleon’s global manufacturing capabilities, with the company deeming the Maidenhead site no longer viable for product manufacture.

The affected production lines, which include popular toothpaste and mouthwash brands like Sensodyne and Parodontax, will see some of their manufacturing operations transferred to Haleon’s facility in Slovakia. 

Haleon’s priority is to ensure that the people impacted are supported through this process,” stated the company spokesperson, acknowledging the difficulty of the decision.

 

 

 

 

The closure will be phased over the next two years, with ongoing consultations to address the impact on affected employees. This decision will lead to the loss of 435 jobs at its Maidenhead facility in Berkshire.

Despite the factory closure, Haleon remains committed to its UK presence, with plans to maintain corporate offices in Weybridge, Surrey, and London.

Additionally, the company is investing £130 million(US$162.87m)in a new research and development site in Weybridge, demonstrating its continued commitment to innovation and growth.

Established in 2019 through the merger of the consumer healthcare businesses of GSK and Pfizer, Haleon operated as a joint venture within GSK before becoming an independent entity listed on the London Stock Exchange in 2022.

With GSK and Pfizer gradually divesting their stakes in the company, Haleon has embarked on a strategic path focused on debt reduction, cost optimization, and brand simplification.

Earlier this year, the company finalized a deal to sell its ChapStick lip balm brand to Suave Brands Company for approximately £400 million (US$510m).

This divestiture follows the sale of the athlete’s foot treatment Lamisil last year, as Haleon continues to streamline its portfolio and strengthen its financial position.

Amidst these changes, Haleon remains dedicated to its mission of delivering high-quality healthcare products to consumers worldwide.

While the closure of its UK factory presents challenges, the company’s ongoing investments and strategic initiatives signal its commitment to sustainable growth and innovation in the global healthcare market.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.